Clinicaltrials.gov identifier:
NCT02401347 (https://clinicaltrials.gov/show/NCT02401347)
Study Contact Information:
The study is being conducted by researchers at Stanford University Hospital. Contact Pei Jen Chang by phone at 310-967-4339 or by email.
The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. This study is no longer enrolling people.
This study is no longer enrolling people.
This study is no longer enrolling people.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.